Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -61.86% is 50% above its 5-year average of -122.74%, near the high end of its 5-year range (-487.69%–79.99%).
6.98% above its 12-month average of -66.50%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.76%.
RETURN ON ASSETS (ROA)
-61.86%
RETURN ON ASSETS (ROA) AVG TTM
-66.50%
RETURN ON ASSETS (ROA) AVG 3Y
-24.17%
RETURN ON ASSETS (ROA) AVG 5Y
-122.74%
RETURN ON ASSETS (ROA) AVG 10Y
-159.28%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.98%
CURRENT VS 3Y AVG
-155.88%
CURRENT VS 5Y AVG
+49.60%
CURRENT VS 10Y AVG
+61.16%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.75%
median of 809 covered companies
CURRENT VS SECTOR MEDIAN
-94.83%
vs the sector median at left
Senseonics Holdings, Inc.
Market Cap
$419.42M
Return on Assets (ROA)
-61.86%
TTM Avg
-66.50%
3Y Avg
-24.17%
5Y Avg
-122.74%
Market Cap
$416.66M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
Market Cap
$422.54M
Return on Assets (ROA)
-86.35%
TTM Avg
-25.00%
3Y Avg
-21.41%
5Y Avg
-20.43%
Market Cap
$425.52M
Return on Assets (ROA)
-6.40%
TTM Avg
-54.29%
3Y Avg
-36.81%
5Y Avg
-26.71%
Market Cap
$425.86M
Return on Assets (ROA)
-31.15%
TTM Avg
-77.61%
3Y Avg
-57.20%
5Y Avg
-46.24%
Market Cap
$411.76M
Return on Assets (ROA)
-14.54%
TTM Avg
-48.52%
3Y Avg
-33.40%
5Y Avg
-26.00%
Market Cap
$411.65M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$410.19M
Return on Assets (ROA)
12.09%
TTM Avg
1.03%
3Y Avg
-6.34%
5Y Avg
-7.45%
Market Cap
$409.99M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Senseonics Holdings, Inc. (SENS) | $419.42M | -61.86% | -66.50% | -24.17% | -122.74% |
| Myriad Genetics, Inc. (MYGN)vs › | $416.66M | -17.62% | -32.09% | -24.12% | -19.05% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $422.54M | -86.35% | -25.00% | -21.41% | -20.43% |
| Tilray Brands, Inc. (TLRY)vs › | $425.52M | -6.40% | -54.29% | -36.81% | -26.71% |
| Editas Medicine, Inc. (EDIT)vs › | $425.86M | -31.15% | -77.61% | -57.20% | -46.24% |
| Prothena Corporation plc (PRTA)vs › | $411.76M | -14.54% | -48.52% | -33.40% | -26.00% |
| Rezolute, Inc. (RZLT)vs › | $411.65M | -68.75% | -55.58% | -51.15% | -46.76% |
| Strata Critical Medical, Inc. (SRTA)vs › | $410.19M | 12.09% | 1.03% | -6.34% | -7.45% |
| Shoulder Innovations, Inc. (SI)vs › | $409.99M | -23.05% | -30.00% | -27.77% | -27.77% |
| Tectonic Therapeutic, Inc. (TECX)vs › | $429.82M | -36.19% | -33.16% | -60.79% | -52.41% |
ROA
-61.9%
ROE
-121.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -54.73% |
| 2024-12-31 | -78.27% |
| 2023-12-31 | -43.69% |
| 2022-12-31 | 79.99% |
| 2021-12-31 | -152.05% |
| 2020-12-31 | -487.69% |
| 2019-12-31 | -87.01% |
| 2018-12-31 | -58.74% |
| 2017-12-31 | -128.64% |
| 2016-12-31 | -197.25% |
| 2015-12-31 | -544.01% |
| 2014-12-31 | -94.45% |
| 2013-12-31 | -187790.00% |
